$7.2 million project using Vaxxas patches for JEV vaccination progresses
The Coalition for Epidemic Preparedness Innovations (CEPI) has approved progression of a $US 4.8 million ($7.2 million) program involving Vaxxas — a Brisbane-based, clinical-stage company developing a needle vaccine delivery platform — and an mRNA Japanese encephalitis vaccine (JEV) from SK bioscience. According to a statement from Vaxxas on Thursday, the program is to develop…